Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated March 21, 2026, titled "Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sun Pharma has launched its semaglutide injection in India under two brand names. Noveltreat is for chronic weight management in adults and comes in five dose strengths (0.25 mg to 2.4 mg), while Sematrinity is for adults with type 2 diabetes and comes in two strengths (2 mg and 4 mg). Both products are priced significantly lower than the existing innovator brand, with weekly therapy costs ranging from ₹900 to ₹2,000 for Noveltreat and ₹750 to ₹1,300 for Sematrinity. The pre-filled pens are manufactured in Europe using devices from leading global pharmaceutical device suppliers. The company has also announced a patient support program to guide patients through their treatment journey. This launch positions Sun Pharma in India's growing GLP-1 market, where obesity affects nearly 1 in 4 adults and over 100 million people live with diabetes.
This launch gives Sun Pharma a direct entry into India's high-growth GLP-1 segment for both obesity and diabetes treatment, with a clear pricing advantage over the innovator brand. Investors should watch for market share gains and revenue contribution from these brands in upcoming quarterly results.